Broad spectrum immune and antiviral gene modulation by oral interferon
An antiviral/immunomodulatory response in an animal is induced by oral administration to an infected animal, including humans, of a human α-interferon. Methods of conferring resistance or mitigating the effects of exposure to a virus including avian influenza are described.
1. A method of mitigating the effects of or conferring resistance to a susceptible viral infection, wherein said viral infection is any pathogen that replicates by a mechanism similar to human or avian influenza virus, comprising, prior to exposure to a virus or shortly after exposure to the virus, but prior to the development of symptoms, orally or nasally administering to an animal α-interferon in an amount of at least 6.6 IU per pound of the animal's body weight so that the effects of the viral infection are mitigated or the resistance is conferred.
2. The method of claim 1 wherein the viral infection is avian influenza.
3. The method of claim 1 wherein the α-interferon is administered orally or nasally to abrogate the “cytokine burst” leading to inappropriate immune response.
4. The method of claim 1 wherein said animal is a human.
5. A method of conferring resistance to or mitigating the effects of an infectious, avian influenza virus; the method comprising: prior to exposure to the virus or shortly after exposure to the virus, respectively, and prior to development of symptoms from infection by the virus, orally or nasally administering multiple, glycosylated α-interferon species to a human patient in an amount of at least 6.6 IU per pound of the patient's body weight so that the resistance is conferred or the effects are mitigated.
6. The method of claim 5 wherein the α-interferon species were purified as a mixture of at least seven species of α-interferon produced by human white blood cells.
7. The method of claim 6 wherein the α-interferon species are orally administered in an amount in the range of 1,000-10,000 IU per day.
8. The method of claim 6 wherein the α-interferon species are orally administered in an amount of at least 6.6 IU per pound of the patient's body weight.
9. The method of claim 8 wherein the α-interferon species are orally administered in an amount in the range of 1,000-10,000 IU per day.
10. The method of claim 6 wherein the α-interferon species are nasally administered in an amount of at least 6.6 IU per pound of the patient's body weight.
11. The method of claim 10 wherein the α-interferon species are nasally administered in an amount in the range of 1,000-10,000 IU per day.
12. The method of claim 6 wherein the α-interferon species are nasally administered in an amount in the range of 1,000-10,000 IU per day.
13. The method of claim 5 wherein the α-interferon species are orally administered in an amount of at least 6.6 IU per pound of the patient's body weight.
14. The method of claim 13 wherein the α-interferon species are orally administered in an amount in the range of 1,000-10,000 IU per day.
15. The method of claim 5 wherein the α-interferon species are orally administered in an amount in the range of 1,000-10,000 IU per day.
16. The method of claim 5 wherein the α-interferon species are nasally administered in an amount of at least 6.6 IU per pound of the patient's body weight.
17. The method of claim 5 wherein the α-interferon species are nasally administered in an amount in the range of 1,000-10,000 IU per day.
18. The method of claim 17 wherein the α-interferon species are nasally administered in an amount in the range of 1,000-10,000 IU per day.
19. The method of claim 5 wherein a “cytokine burst” leading to inappropriate immune response is abrogated.